Abstract
Thediazabicyclic molecule bispidine named by the chemist Carl Mannich in 1930, is a naturally occurring scaffold with interesting features. Bispidine can form different conformers, has high basicity, can attack dichloromethane, has metal ion coordination properties and interacts with nicotinic acetylcholine receptors. In this review we will discuss important properties, synthetic pathways and biological activities of bispidine and some derivatives. Bispidine can function as a scaffold for compounds with very diverse biological activities, e.g. interacting with ion channels, G-protein coupled receptors, and enzymes, and is even used for the development of new in vivo radiotracers.
Keywords: Bispidine, cytisine, 3, 7-diazabicyclo[3.3.1]nonane, radiotracer, receptor, scaffold, sparteine.Bispidine, cytisine, 3, 7-diazabicyclo[3.3.1]nonane, radiotracer, receptor, scaffold, sparteine.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Bispidine as a Privileged Scaffold
Volume: 16 Issue: 11
Author(s): Isabelle Tomassoli and Daniela Gündisch
Affiliation:
Keywords: Bispidine, cytisine, 3, 7-diazabicyclo[3.3.1]nonane, radiotracer, receptor, scaffold, sparteine.Bispidine, cytisine, 3, 7-diazabicyclo[3.3.1]nonane, radiotracer, receptor, scaffold, sparteine.
Abstract: Thediazabicyclic molecule bispidine named by the chemist Carl Mannich in 1930, is a naturally occurring scaffold with interesting features. Bispidine can form different conformers, has high basicity, can attack dichloromethane, has metal ion coordination properties and interacts with nicotinic acetylcholine receptors. In this review we will discuss important properties, synthetic pathways and biological activities of bispidine and some derivatives. Bispidine can function as a scaffold for compounds with very diverse biological activities, e.g. interacting with ion channels, G-protein coupled receptors, and enzymes, and is even used for the development of new in vivo radiotracers.
Export Options
About this article
Cite this article as:
Tomassoli Isabelle and Gündisch Daniela, Bispidine as a Privileged Scaffold, Current Topics in Medicinal Chemistry 2016; 16 (11) . https://dx.doi.org/10.2174/1568026615666150915111434
DOI https://dx.doi.org/10.2174/1568026615666150915111434 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Macronutrient Specific Postprandial Oxidative Stress: Relevance to the Development of Insulin Resistance
Current Diabetes Reviews Cellular and Physiological Effects of Soy Flavonoids
Mini-Reviews in Medicinal Chemistry Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?
Current Pharmaceutical Design Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective
Current Hypertension Reviews Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen
Vascular Disease Prevention (Discontinued) Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Depression in Older Persons with Mobility Limitations
Current Pharmaceutical Design Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]
Current Pharmaceutical Design Inodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets